Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 21.95% is 33% below its 5-year average of 32.56%, near the high end of its 5-year range (-139.07%–52.80%).
54.57% below its 12-month average of 48.31%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 52.80%.
GROSS MARGIN
21.95%
GROSS MARGIN AVG TTM
48.31%
GROSS MARGIN AVG 3Y
39.44%
GROSS MARGIN AVG 5Y
32.56%
GROSS MARGIN AVG 10Y
33.91%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-54.57%
CURRENT VS 3Y AVG
-44.35%
CURRENT VS 5Y AVG
-32.60%
CURRENT VS 10Y AVG
-35.27%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-46.96%
vs the sector median at left
Bionano Genomics, Inc.
Market Cap
$16.87M
Gross Margin
21.95%
TTM Avg
48.31%
3Y Avg
39.44%
5Y Avg
32.56%
Market Cap
$16.84M
Gross Margin
0.00%
TTM Avg
-52.16%
3Y Avg
-139.89%
5Y Avg
-776.52%
Market Cap
$16.53M
Gross Margin
72.24%
TTM Avg
86.12%
3Y Avg
93.06%
5Y Avg
-220.71%
Market Cap
$17.07M
Gross Margin
-334.26%
TTM Avg
-117.13%
3Y Avg
-347.18%
5Y Avg
-222.70%
Market Cap
$16.50M
Gross Margin
-88.25%
TTM Avg
-11.22%
3Y Avg
9.24%
5Y Avg
11.19%
Market Cap
$17.14M
Gross Margin
99.63%
TTM Avg
49.76%
3Y Avg
72.18%
5Y Avg
92.05%
Market Cap
$17.14M
Gross Margin
-354.93%
TTM Avg
-228.26%
3Y Avg
-369.25%
5Y Avg
-249.00%
Market Cap
$17.84M
Gross Margin
10.27%
TTM Avg
10.01%
3Y Avg
10.00%
5Y Avg
11.56%
Market Cap
$15.78M
Gross Margin
0.00%
TTM Avg
-3731.89%
3Y Avg
-2384.22%
5Y Avg
-1567.12%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bionano Genomics, Inc. (BNGO) | $16.87M | 21.95% | 48.31% | 39.44% | 32.56% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | 0.00% | -52.16% | -139.89% | -776.52% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.53M | 72.24% | 86.12% | 93.06% | -220.71% |
| Lipocine Inc. (LPCN)vs › | $17.07M | -334.26% | -117.13% | -347.18% | -222.70% |
| Dyadic International, Inc. (DYAI)vs › | $16.50M | -88.25% | -11.22% | 9.24% | 11.19% |
| Palatin Technologies, Inc. (PTN)vs › | $17.14M | 99.63% | 49.76% | 72.18% | 92.05% |
| PAVmed Inc. (PAVM)vs › | $17.14M | -354.93% | -228.26% | -369.25% | -249.00% |
| Cosmos Health Inc. (COSM)vs › | $17.84M | 10.27% | 10.01% | 10.00% | 11.56% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | 0.00% | -3731.89% | -2384.22% | -1567.12% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.65M | 107.54% | 50.00% | 25.00% | 16.67% |
Gross Margin
21.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 52.80% |
| 2026-03-31 | 48.63% |
| 2025-12-31 | 42.75% |
| 2025-09-30 | 45.74% |
| 2025-06-30 | 51.64% |
| 2025-03-31 | 45.50% |
| 2024-12-31 | 41.86% |
| 2024-09-30 | -139.07% |
| 2024-06-30 | 33.26% |
| 2024-03-31 | 32.20% |
| 2023-12-31 | 22.74% |
| 2023-09-30 | 29.50% |
| 2023-06-30 | 26.65% |
| 2023-03-31 | 27.92% |
| 2022-12-31 | 21.97% |
| 2022-09-30 | 25.05% |
| 2022-06-30 | 22.05% |
| 2022-03-31 | 15.12% |
| 2021-12-31 | 3.79% |
| 2021-09-30 | 24.79% |
| 2021-06-30 | 37.32% |
| 2021-03-31 | 32.92% |
| 2020-12-31 | 29.55% |
| 2020-09-30 | 33.52% |
| 2020-06-30 | 48.98% |
| 2020-03-31 | 24.65% |
| 2019-12-31 | 39.38% |
| 2019-09-30 | 28.31% |
| 2019-06-30 | 28.48% |
| 2019-03-31 | 38.09% |
| 2018-12-31 | 25.55% |
| 2018-09-30 | -8.47% |
| 2018-06-30 | 46.51% |
| 2018-03-31 | 52.42% |
| 2017-12-31 | 47.41% |
| 2017-09-30 | 38.38% |
| 2017-06-30 | 25.37% |
| 2017-03-31 | 29.96% |
